Tempus AI

Tempus AI operates a precision medicine platform that combines genomic sequencing, clinical data, and artificial intelligence to assist healthcare providers, pharmaceutical companies, and patients in making more informed treatment decisions. The company has built a network spanning approximately 65% of academic medical centers and over 50% of oncologists in the United States, with particular strength in oncology care and clinical trial matching.

The platform offers four core technology products: ONE (AI assistant for providers), NEXT (care gap identification), LENS (real-world data analytics), and ALGOS (algorithmic models connected to diagnostic assays). Tempus maintains a dataset of over 40 million de-identified research records and 350+ petabytes of data. The company recently acquired Paige to expand its digital pathology capabilities and received FDA 510(k) clearance for its ECG-Low EF cardiovascular diagnostic software.

Tempus serves three primary customer segments: healthcare providers seeking molecular profiling and treatment guidance, life sciences companies requiring real-world evidence for drug development, and patients looking for personalized therapy options and clinical trial opportunities. The company has established partnerships with 95% of the top 20 pharma oncology companies and maintains over 250 biopharma partnerships.

Choose Tempus when your organization requires an established precision medicine infrastructure with proven scale in oncology care. The company excels in scenarios requiring integration of genomic testing, clinical trial matching, and real-world evidence generation within a single platform. Their recent expansion into cardiovascular diagnostics and digital pathology indicates growing capabilities beyond oncology.

Expect a data-driven partnership with access to extensive molecular profiling capabilities, AI-enabled clinical decision support tools, and potential integration with EHR systems. The Northwestern Medicine implementation of their David AI co-pilot demonstrates capability for deep health system integration. Organizations should anticipate enterprise-scale engagements with focus on long-term data partnerships rather than one-off projects.

Tempus operates exclusively in healthcare with a primary concentration in oncology precision medicine. The company serves three distinct healthcare verticals: provider organizations (academic medical centers, health systems, oncology practices), life sciences companies (pharmaceutical and biotech firms conducting drug development), and patients (through physician-ordered testing and clinical trial matching). Their healthcare-specific capabilities include HIPAA-compliant genomic sequencing, clinical trial matching services, and FDA-cleared diagnostic algorithms.

Recent expansion into cardiovascular diagnostics through FDA 510(k) clearance for ECG analysis and digital pathology via the Paige acquisition indicates diversification beyond oncology while maintaining healthcare-exclusive focus. The company's real-world data platform specifically addresses healthcare research needs with de-identified clinical and molecular data.

The ideal Tempus client is a large academic medical center, health system, or comprehensive cancer center seeking to implement precision medicine programs at scale. Pharmaceutical and biotech companies conducting oncology clinical trials and requiring real-world evidence for regulatory submissions or drug development represent another core client profile. Organizations must be prepared for enterprise-level implementations and have sufficient patient volume to justify platform integration costs.